Brief: Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI
06/02/2026 13:30
Feb 6 (Reuters) - Clearmind Medicine Inc CMND.O: CLEARMIND MEDICINE ENTERS INTO DEVELOPMENT AGREEMENT TO ADVANCE INTRANASAL FORMULATION FOR ITS PROPRIETARY NON-HALLUCINOGENIC NEUROPLASTOGEN MEAI Source text: ID:nGNX8L1NC0 Further company coverage: CMND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearmind Medicine
See all newsBrief: Clearmind Advances Dialogue With U.S. Federal Government On Psychedelic Therapies, Submitting Recommendations To FDA
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM